The flavonoid nobiletin inhibits tumor growth and angiogenesis of ovarian cancers via the Akt pathway

International Journal of Oncology

Volumn 46, Issue 6, 2015, Pages 2629-2638

  Chen, Jianchu ^a,b   Chen, Allen Y ^c   Huang, Haizhi ^a,b   Ye, Xingqian ^a   Rollyson, William D ^d   Perry, Haley E ^d   Brown, Kathleen C ^d   Rojanasakul, Yon ^c   Rankin, Gary O ^d   Dasgupta, Piyali ^d   Chen, Yi Charlie ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b Alderson Broaddus College   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; Angiogenesis; HIF 1 ; Nobiletin; Ovarian cancer; Vascular epithelial growth factor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOBILETIN; PROTEIN KINASE B; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FLAVONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CELL VIABILITY; CHORIOALLANTOIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; NONHUMAN; NUDE MOUSE; ONCOGENE C MYC; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; TUMOR VOLUME; ANIMAL; CHICK EMBRYO; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; MALE; METABOLISM; MOUSE; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; FEMALE; FLAVONES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928580755     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2946     Document Type: Article

References (61)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ; American Cancer Society: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
2. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
3. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z and Mills GB: CA 125: The past and the future. Int J Biol Markers 13: 179-187, 1998.
4. Winstead ER: Ovarian cancer study raises questions about developing markers for early detection. NCI cancer bulletin [On-line serial], 8 (5). Available ncicancerbulletin@mail.nih.gov Message: NCI Cancer Bulletin, March 8, 2011.
5. Fishman DA and Schwartz PE: Current approaches to diagnosis and treatment of ovarian germ cell malignancies. Curr Opin Obstet Gynecol 6: 98-104, 1994.
6. Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics, 2001. CA Cancer J Clin 51: 15-36, 2001.
7. Bosetti C, Rossi M, McLaughlin JK, Negri E, Talamini R, Lagiou P, Montella M, Ramazzotti V, Franceschi S and LaVecchia C: Flavonoids and the risk of renal cell carcinoma. Cancer Epidemiol Biomarkers Prev 16: 98-101, 2007.
8. Bosetti C, Bravi F, Talamini R, Parpinel M, Gnagnarella P, Negri E, Montella M, Lagiou P, Franceschi S and La Vecchia C: Flavonoids and prostate cancer risk: A study in Italy. Nutr Cancer 56: 123-127, 2006.
9. Theodoratou E, Kyle J, Cetnarskyj R, Farrington SM, Tenesa A, Barnetson R, Porteous M, Dunlop M and Campbell H: Dietary flavonoids and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 16: 684-693, 2007.
10. Adhami VM, Malik A, Zaman N, Sarfaraz S, Siddiqui IA, Syed DN, Afaq F, Pasha FS, Saleem M and Mukhtar H: Combined inhibitory effects of green tea polyphenols and selective cyclo-oxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res 13: 1611-1619, 2007.
11. Choi EJ, Kim T and Lee MS: Pro-apoptotic effect and cytotoxicity of genistein and genistin in human ovarian cancer SK-OV-3 cells. Life Sci 80: 1403-1408, 2007.
12. Seo HS, DeNardo DG, Jacquot Y, Laïos I, Vidal DS, Zambrana CR, Leclercq G and Brown PH: Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res Treat 99: 121-134, 2006.
13. Fang J, Zhou Q, Liu LZ, Xia C, Hu X, Shi X and Jiang BH: Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 28: 858-864, 2007.
14. Birt DF, Hendrich S and Wang W: Dietary agents in cancer prevention: Flavonoids and isoflavonoids. Pharmacol Ther 90: 157-177, 2001.
15. Gossner G, Choi M, Tan L, Fogoros S, Griffith KA, Kuenker M and Liu JR: Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells. Gynecol Oncol 105: 23-30, 2007.
16. Spinella F, Rosanò L, Di Castro V, Decandia S, Albini A, Nicotra MR, Natali PG and Bagnato A: Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Mol Cancer Ther 5: 1483-1492, 2006.
17. Brusselmans K, Vrolix R, Verhoeven G and Swinnen JV: Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem 280: 5636-5645, 2005.
18. Nogata Y, Sakamoto K, Shiratsuchi H, Ishii T, Yano M and Ohta H: Flavonoid composition of fruit tissues of citrus species. Biosci Biotechnol Biochem 70: 178-192, 2006.
19. Murakami A, Nakamura Y, Torikai K, Tanaka T, Koshiba T, Koshimizu K, Kuwahara S, Takahashi Y, Ogawa K, Yano M, et al: Inhibitory effect of citrus nobiletin on phorbol ester-induced skin inflammation, oxidative stress, and tumor promotion in mice. Cancer Res 60: 5059-5066, 2000.
20. Kohno H, Yoshitani S, Tsukio Y, Murakami A, Koshimizu K, Yano M, Tokuda H, Nishino H, Ohigashi H and Tanaka T: Dietary administration of citrus nobiletin inhibits azoxymethane-induced colonic aberrant crypt foci in rats. Life Sci 69: 901-913, 2001.
21. Suzuki R, Kohno H, Murakami A, Koshimizu K, Ohigashi H, Yano M, Tokuda H, Nishino H and Tanaka T: Citrus nobiletin inhibits azoxymethane-induced large bowel carcinogenesis in rats. Biofactors 22: 111-114, 2004.
22. Lam KH, Alex D, Lam IK, Tsui SK, Yang ZF and Lee SM: Nobiletin, a polymethoxylated flavonoid from citrus, shows antiangiogenic activity in a zebrafish in vivo model and HUVEC in vitro model. J Cell Biochem 112: 3313-3321, 2011.
23. Kunimasa K, Ikekita M, Sato M, Ohta T, Yamori Y, Ikeda M, Kuranuki S and Oikawa T: Nobiletin, a citrus polymethoxyflavonoid, suppresses multiple angiogenesis-related endothelial cell functions and angiogenesis in vivo. Cancer Sci 101: 2462-2469, 2010.
24. Kunimasa K, Kuranuki S, Matsuura N, Iwasaki N, Ikeda M, Ito A, Sashida Y, Mimaki Y, Yano M, Sato M, et al: Identification of nobiletin, a polymethoxyflavonoid, as an enhancer of adiponectin secretion. Bioorg Med Chem Lett 19: 2062-2064, 2009.
25. Saito T, Abe D and Sekiya K: Nobiletin enhances differentiation and lipolysis of 3T3-L1 adipocytes. Biochem Biophys Res Commun 357: 371-376, 2007.
26. Miyata Y, Sato T, Yano M and Ito A: Activation of protein kinase C βII/å-c-Jun NH2-terminal kinase pathway and inhibition of mitogen-activated protein/extracellular signal-regulated kinase 1/2 phosphorylation in antitumor invasive activity induced by the polymethoxy flavonoid, nobiletin. Mol Cancer Ther 3: 839-847, 2004.
27. Miyata Y, Sato T, Imada K, Dobashi A, Yano M and Ito A: A citrus polymethoxyflavonoid, nobiletin, is a novel MEK inhibitor that exhibits antitumor metastasis in human fibrosarcoma HT-1080 cells. Biochem Biophys Res Commun 366: 168-173, 2008.
28. Luo H, Li B, Li Z, Cutler SJ, Rankin GO and Chen YC: Chaetoglobosin K inhibits tumor angiogenesis through downregulation of vascular epithelial growth factor-binding hypoxia-inducible factor 1α. Anticancer Drugs 24: 715-724, 2013.
29. Fang J, Cao Z, Chen YC, Reed E and Jiang BH: 9-β-D-Arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells. Mol Pharmacol 66: 178-186, 2004.
30. Blancher C, Moore JW, Robertson N and Harris AL: Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1α, HIF-2 α, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Cancer Res 61: 7349-7355, 2001.
31. Laughner E, Taghavi P, Chiles K, Mahon PC and Semenza GL: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004, 2001.
32. Stiehl DP, Jelkmann W, Wenger RH and Hellwig-Bürgel T: Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett 512: 157-162, 2002.
33. Miura T, Chiba M, Kasai K, Nozaka H, Nakamura T, Shoji T, Kanda T, Ohtake Y and Sato T: Apple procyanidins induce tumor cell apoptosis through mitochondrial pathway activation of caspase-3. Carcinogenesis 29: 585-593, 2008.
34. Jeong WS and Kong ANT: Biological properties of monomeric and polymeric catechins: Green tea catechins and procyanidins. Pharm Biol 42 (s1): 84-93, 2004.
35. Luo H, Rankin GO, Juliano N, Jiang BH and Chen YC: Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERK-NFκB-c-Myc-p21 pathway. Food Chem 130: 321-328, 2012.
36. Chu EC and Tarnawski AS: PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit 10: RA235-RA241, 2004.
37. Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004.
38. Ferrara N: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 (Suppl 1): 2-10, 2004.
39. Ramakrishnan S, Subramanian IV, Yokoyama Y and Geller M: Angiogenesis in normal and neoplastic ovaries. Angiogenesis 8: 169-182, 2005.
40. Hazelton D, Nicosia RF and Nicosia SV: Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res 5: 823-829, 1999.
41. Alvarez AA, Krigman HR, Whitaker RS, Dodge RK and Rodriguez GC: The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 5: 587-591, 1999.
42. Duyndam MC, Hilhorst MC, Schlüper HM, Verheul HM, van Diest PJ, Kraal G, Pinedo HM and Boven E: Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol 160: 537-548, 2002.
43. Hefler LA, Mustea A, Könsgen D, Concin N, Tanner B, Strick R, Heinze G, Grimm C, Schuster E, Tempfer C, et al: Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res 13: 898-901, 2007.
44. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD and Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613, 1996.
45. Lam IK, Alex D, Wang YH, Liu P, Liu AL, Du GH and Lee SM: In vitro and in vivo structure and activity relationship analysis of polymethoxylated flavonoids: Identifying sinensetin as a novel antiangiogenesis agent. Mol Nutr Food Res 56: 945-956, 2012.
46. Luo H, Rankin GO, Liu L, Daddysman MK, Jiang BH and Chen YC: Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells. Nutr Cancer 61: 554-563, 2009.
47. Jiang BH and Liu LZ: AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets 8: 19-26, 2008.
48. Hu L, Hofmann J and Jaffe RB: Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma. Clin Cancer Res 11: 8208-8212, 2005.
49. Shi MD, Liao YC, Shih YW and Tsai LY: Nobiletin attenuates metastasis via both ERK and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells. Phytomedicine 20: 743-752, 2013.
50. Lee YC, Cheng TH, Lee JS, Chen JH, Liao YC, Fong Y, Wu CH and Shih YW: Nobiletin, a citrus flavonoid, suppresses invasion and migration involving FAK/PI3K/Akt and small GTPase signals in human gastric adenocarcinoma AGS cells. Mol Cell Biochem 347: 103-115, 2011.
51. Kar S, Palit S, Ball WB and Das PK: Carnosic acid modulates Akt/IKK/NF-κB signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells. Apoptosis 17: 735-747, 2012.
52. Kim MO, Moon DO, Heo MS, Lee JD, Jung JH, Kim SK, Choi YH and Kim GY: Pectenotoxin-2 abolishes constitutively activated NF-κB, leading to suppression of NF-κ B related gene products and potentiation of apoptosis. Cancer Lett 271: 25-33, 2008.
53. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and Donner DB: NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82-85, 1999.
54. van Uden P, Kenneth NS and Rocha S: Regulation of hypoxia-inducible factor-1α by NF-kappaB. Biochem J 412: 477-484, 2008.
55. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436, 2006.
56. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, et al: Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 13: 3423-3430, 2007.
57. Gonzalez-Perez RR, Xu Y, Guo S, Watters A, Zhou W and Leibovich SJ: Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkappaB/HIF-1alpha activation. Cell Signal 22: 1350-1362, 2010.
58. Testa JR and Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98: 10983-10985, 2001.
59. + inhibit cytochrome c-dependent formation of the apoptosome. J Biol Chem 276: 41985-41990, 2001.
60. Arafa SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA and Wani AA: Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res 69: 8910-8917, 2009.
61. Luo H, Daddysman MK, Rankin GO, Jiang BH and Chen YC: Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of c-Myc. Cancer Cell Int 10: 16, 2010.